Home › Funds › Vivo Capital, LLC › FTH
Vivo Capital, LLC position in FTH
Faeth Therapeutics Inc
Vivo Capital, LLC reported holding 844,576 shares of FTH (Faeth Therapeutics Inc) in its Q3 2026 13F filing — a position valued at US$25.1M, representing 2.85% of its reported portfolio and ranking #13 among its reported holdings. Vivo Capital, LLC has disclosed FTH holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's FTH position evolved
Vivo Capital, LLC first disclosed a stake in FTH in Q1 2026 at 722,020 shares (US$22.8M). The position peaked in Q3 2026 at 844,576 shares, worth US$25.1M. Across 3 filings, Vivo Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 844,576 shares valued at US$25.1M — an increase of 122,556 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 722.02K | $22.76M | New |
| Q2 2026 | 722.02K | $18.05M | Hold |
| Q3 2026 | 844.58K | $25.12M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FTH and 13F data
FTH (Faeth Therapeutics Inc) is a company whose sector is not yet classified in our data. 60 other funds we track also report a position in FTH — the largest reported positions include MONTANOVA CAPITAL, LLC (US$50.5M), Avoro Capital Advisors LLC (US$36.1M), BAKER BROS. ADVISORS LP (US$32.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FTH
- MONTANOVA CAPITAL, LLC 2.02M sh · $50.50M · Q2 2026
- Avoro Capital Advisors LLC 1.44M sh · $36.10M · Q2 2026
- BAKER BROS. ADVISORS LP 1.29M sh · $32.16M · Q2 2026
- Fairmount Funds Management LLC 722.02K sh · $18.05M · Q2 2026
- Logos Global Management LP 722.02K sh · $18.05M · Q2 2026
- Caligan Partners LP 629.47K sh · $15.74M · Q2 2026
- B Group, Inc. 610.17K sh · $15.25M · Q2 2026
- Trails Edge Capital Partners, LP 515.34K sh · $12.88M · Q2 2026
- Octagon Capital Advisors LP 361.01K sh · $9.03M · Q2 2026
- Cormorant Asset Management, LP 1.03M sh · $7.66M · Q2 2026
- Boxer Capital Management, LLC 180.50K sh · $4.51M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 124.10K sh · $3.69M · Q3 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held FTH?
Vivo Capital, LLC has disclosed FTH holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Vivo Capital, LLC's current position in FTH?
As of Q3 2026, Vivo Capital, LLC holds 844.58K shares of FTH (Faeth Therapeutics Inc), valued at $25.12M, representing 2.85% of its reported portfolio and ranking #13.
Has Vivo Capital, LLC been buying or selling FTH?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC increased its position in FTH. The position peaked in Q3 2026 at 844.58K shares.
Which other funds hold FTH?
Other major institutional holders of FTH include MONTANOVA CAPITAL, LLC, Avoro Capital Advisors LLC, BAKER BROS. ADVISORS LP, among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.